U.S. License Holder:
Kashiv Biosciences LLC / Amneal
Date of License:
May-26-2022
Last Update:
January-23-2023
FDA-Approved Indications
FYLNETRA (pegfilgrastim-pbbk) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.